



**MEDICARE FORM**  
**Lemtrada® (alemtuzumab)**  
**Medication Precertification Request**

Page 1 of 3

(All fields must be completed and legible for precertification review.)

For Medicare Advantage Part B:  
For other lines of business:  
Please use commercial form.  
Note: Lemtrada is non-preferred.  
The preferred product is Ocrevus

Would you like to use electronic prior authorization? Consider using **Availity**, our electronic prior authorization portal. Learn more about **Availity** from the links in the table below.

For phone or fax requests, refer to the table below for routing information. To determine which box to use, refer to the patient's Aetna ID card. State specific special needs and Medicare-Medicaid Plans may be designated on the front of the ID card or in the website URL on the back of the card. If you don't see your specific plan listed, call the number on the back of the member's ID card to confirm routing information.

<p>For <b>Aetna Medicare Advantage</b> and <b>Allina Health Aetna Medicare</b> members send request to: <b>Phone:</b> <a href="tel:1-866-503-0857">1-866-503-0857</a> (TTY: <a href="tel:1-866-503-0857">711</a>) <b>Fax:</b> <a href="tel:1-844-268-7263">1-844-268-7263</a> <b>Availity:</b> <a href="https://www.aetna.com/health-care-professionals/resource-center/availability.html">https://www.aetna.com/health-care-professionals/resource-center/availability.html</a></p>
<p>For Aetna Medicare Advantage <b>Virginia Dual Eligible Special Needs Plans</b> (HMO D-SNP) send request to: <b>Phone:</b> <a href="tel:1-855-463-0933">1-855-463-0933</a> <b>Fax:</b> <a href="tel:1-833-280-5224">1-833-280-5224</a> <b>Availity:</b> <a href="https://www.aetnabetterhealth.com/virginia-hmosnp/providers/portal">https://www.aetnabetterhealth.com/virginia-hmosnp/providers/portal</a></p>
<p>For Aetna Assure Premier Plus Medicare Advantage <b>New Jersey Dual Eligible Special Needs Plans</b> (HMO D-SNP) send request to: <b>Phone:</b> <a href="tel:1-844-362-0934">1-844-362-0934</a> <b>Fax:</b> <a href="tel:1-833-322-0034">1-833-322-0034</a> <b>Availity:</b> <a href="https://www.aetnabetterhealth.com/new-jersey-hmosnp/providers/portal.html">https://www.aetnabetterhealth.com/new-jersey-hmosnp/providers/portal.html</a></p>
<p>For Aetna Better Health of <b>Illinois Premier Medicare Medicaid Plan</b> (MMP) send request to: <b>Phone:</b> <a href="tel:1-866-600-2139">1-866-600-2139</a> <b>FAX:</b> <a href="tel:1-855-320-8445">1-855-320-8445</a> <b>Availity:</b> <a href="https://www.aetnabetterhealth.com/illinois/providers/portal">https://www.aetnabetterhealth.com/illinois/providers/portal</a></p>
<p>For Aetna Better Health of <b>Ohio Premier Medicare Medicaid Plan</b> (MMP) send request to: <b>Phone:</b> <a href="tel:1-855-364-0974">1-855-364-0974</a> <b>Fax:</b> <a href="tel:1-855-734-9389">1-855-734-9389</a> <b>Availity:</b> <a href="https://www.aetnabetterhealth.com/ohio/providers/portal">https://www.aetnabetterhealth.com/ohio/providers/portal</a></p>
<p>For Aetna Better Health of <b>Michigan Premier Medicare Medicaid Plan</b> (MMP) send request to: <b>Phone:</b> <a href="tel:1-855-676-5772">1-855-676-5772</a> <b>Fax:</b> <a href="tel:1-844-241-2495">1-844-241-2495</a> <b>Availity:</b> <a href="https://www.aetnabetterhealth.com/michigan/providers/portal.html">https://www.aetnabetterhealth.com/michigan/providers/portal.html</a></p>



**MEDICARE FORM**  
**Lemtrada® (alemtuzumab)**  
**Medication Precertification Request**

**For Medicare Advantage Part B:**  
**For other lines of business:**  
 Please use commercial form.  
**Note: Lemtrada is non-preferred.**  
**The preferred product is Ocrevus**

Page 2 of 3

(All fields must be completed and legible for precertification review.)

**Please indicate:**  Start of treatment: Start date \_\_\_\_ / \_\_\_\_ / \_\_\_\_  
 Continuation of therapy: Date of last treatment \_\_\_\_ / \_\_\_\_ / \_\_\_\_

**Precertification Requested By:** \_\_\_\_\_ **Phone:** \_\_\_\_\_ **Fax:** \_\_\_\_\_

**A. PATIENT INFORMATION**

First Name:		Last Name:			
Address:		City:		State:	ZIP:
Home Phone:		Work Phone:		Cell Phone:	
DOB:	Allergies:			E-mail:	
Current Weight: _____ lbs or _____ kgs		Height: _____ inches or _____ cms			

**B. INSURANCE INFORMATION**

Aetna Member ID #: _____	Does patient have other coverage? <input type="checkbox"/> Yes <input type="checkbox"/> No
Group #: _____	If yes, provide ID#: _____ Carrier Name: _____
Insured: _____	Insured: _____

**C. PRESCRIBER INFORMATION**

First Name:		Last Name:				(Check One): <input type="checkbox"/> M.D. <input type="checkbox"/> D.O. <input type="checkbox"/> N.P. <input type="checkbox"/> P.A.	
Address:		City:		State:	ZIP:		
Phone:	Fax:	St Lic #:	NPI #:	DEA #:	UPIN:		
Provider Email:		Office Contact Name:			Phone:		

**D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION**

<b>Place of Administration:</b> <input type="checkbox"/> Self-administered <input type="checkbox"/> Physician's Office <input type="checkbox"/> Outpatient Infusion Center Phone: _____ Center Name: _____ <input type="checkbox"/> Home Infusion Center Phone: _____ Agency Name: _____ <input type="checkbox"/> Administration code(s) (CPT): _____ Address: _____ City: _____ State: _____ ZIP: _____ Phone: _____ Fax: _____ <b>TIN:</b> _____ <b>PIN:</b> _____ <b>NPI:</b> _____	<b>Dispensing Provider/Pharmacy:</b> <input type="checkbox"/> Physician's Office <input type="checkbox"/> Retail Pharmacy <input type="checkbox"/> Specialty Pharmacy <input type="checkbox"/> Mail Order <input type="checkbox"/> Other: _____ Name: _____ Address: _____ City: _____ State: _____ ZIP: _____ Phone: _____ Fax: _____ <b>TIN:</b> _____ <b>PIN:</b> _____ <b>NPI:</b> _____
---	---

**E. PRODUCT INFORMATION**

**Request is for Lemtrada: Dose:** \_\_\_\_\_ **Frequency:** \_\_\_\_\_ **HCPSC Code:** \_\_\_\_\_

**F. DIAGNOSIS INFORMATION** – Please indicate primary ICD Code and specify any other where applicable.

**Primary ICD Code:** \_\_\_\_\_ **Secondary ICD Code:** \_\_\_\_\_ **Other ICD Code:** \_\_\_\_\_

**G. CLINICAL INFORMATION** – Required clinical information must be completed in its entirety for all precertification requests.

**For Initiation Requests:**  
**Note: Lemtrada is non-preferred. The preferred product is Ocrevus.**  
 Yes  No Has the patient had prior therapy with Lemtrada (alemtuzumab) within the last 365 days?  
 Yes  No Has the patient had a trial and failure of Ocrevus (ocrelizumab)?  
     → When was the member's trial and failure of Ocrevus? \_\_\_\_\_  
     → Please describe the nature of the failure of Ocrevus. \_\_\_\_\_  
 Yes  No Has the patient had an adverse reaction to Ocrevus (ocrelizumab)?  
     → When was the member's adverse reaction to Ocrevus? \_\_\_\_\_  
     → Please describe the nature of the adverse reaction to Ocrevus. \_\_\_\_\_  
 Please explain if there are any contraindications or other medical reason(s) that the patient cannot use Ocrevus (ocrelizumab). \_\_\_\_\_  
 Please indicate the type of multiple sclerosis the patient has been diagnosed with:  
 Relapsing-remitting (RRMS)  Secondary-progressive MS (SPMS)  Primary-progressive MS (PPMS)  Progressive-relapsing MS (PRMS)  
 Yes  No Has the patient discontinued other medications used for treating MS (not including Ampyra)?  
 Yes  No Has the patient had an inadequate response to two or more drugs indicated for relapsing forms of multiple sclerosis despite adequate duration of treatment?  
 Yes  No Will a maximum of two courses of Lemtrada be utilized?  
 Please indicate the patient's HIV status:  Positive  Negative  Unknown

Continued on next page



MEDICARE FORM

Lemtrada® (alemtuzumab)

Medication Precertification Request

Page 3 of 3

(All fields must be completed and legible for precertification review.)

For Medicare Advantage Part B:
For other lines of business:
Please use commercial form.

Note: Lemtrada is non-preferred.
The preferred product is Ocrevus

Patient First Name Patient Last Name Patient Phone Patient DOB

G. CLINICAL INFORMATION (continued) - Required clinical information must be completed in its entirety for all precertification requests.

For Continuation requests:

- Is this continuation request a result of the patient receiving samples of Lemtrada?
Does the patient have a documented severe and/or potentially life threatening adverse event that occurred during or following the previous infusion?
Could the adverse reaction be managed through pre-medication in the office setting?

Please indicate How many doses of requested medication has the patient received previously: 0 1-4 5 or more

- Has the patient been receiving benefit from therapy?
Will the patient start treatment at least 12 months after the last dose of the prior treatment course?

H. ACKNOWLEDGEMENT

Request Completed By (Signature Required): Date:

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.